ALNYLAM PHARMACEUTICALS, INC. Uncategorized Contracts & Agreements

53 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Amendment No
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2024
Letter Agreement, effective as of March 1, 2024, between the Company and Indrani L. Franchini
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2024
Letter Agreement, dated July 31, 2023, between Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
MA
2023
Amendment No. 1 entered into as
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2023
Cross-License Agreement dated as of November 12, 2012 by and among the Registrant, Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) and Protiva...
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2023
Form of Capped Call Transaction Confirmation
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2022
Letter Agreement between the Registrant and
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2022
Letter Agreement effective as of October 26, 2021 between the Company and John M. Maraganore, Ph.D
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2021
Letter Agreement between the Registrant and Laurie B. Keating dated September 6, 2021
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2021
Supplemental Agreement effective July 27, 2009 by and among the
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2021
Amendment No. 1 to Sponsored Research Agreement dated as of July 27, 2009
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2021
Sponsored Research Agreement dated as of July 27, 2009 by and among the
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2021
Letter Agreement between the Registrant and Barry E. Greene dated August 26, 2020
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2020
First Amendment to
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2020
Co-Development Agreement between the Registrant and BXLS
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2020
Patent Cross-License Agreement dated April 3, 2020 between Dicerna Pharmaceuticals, Inc. and the Registrant
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
NY
2020
Amended and Restated Investor Agreement dated as of April 8, 2019 by and between the Registrant and Genzyme Corporation
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2019
Investor Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
MA
2019
300 Third Street Cambridge MA, 02142 main ###-###-#### fax ###-###-####
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2017
300 Third StreetCambridge MA, 02142main 617.551.8200fax ###-###-####
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2017
300 ThirdStreet Cambridge MA, 02142 main ###-###-#### fax ###-###-####
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2016
LETTER AGREEMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2014
INVESTOR AGREEMENT BYAND BETWEEN GENZYME CORPORATION AND ALNYLAMPHARMACEUTICALS, INC. DATED AS OF FEBRUARY 27, 2014
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2014
FIRST AMENDMENT TO RIGHTS AGREEMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2014
65 Hayden Avenue, Lexington, MA 02421 P ###-###-#### F ###-###-#### www.cubist.com
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2013
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2013
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2013
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
MA
2013
[Signature Page follows]
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2012
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2012
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2011
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2011
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
2011
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
MA
2011
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
MA
2011
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
MA
2011
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
NY
2011
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2011
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2011
EX-101 INSTANCE DOCUMENT
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
DE
2011